Methadon Hcl Teva

Methadone Hydrochloride, the active ingredient in Methadon Hcl Teva, is a synthetic opioid presented as an oral formulation for oral use. It is employed in the management of opioid dependence and chronic pain, primarily in adult patients who require long‑term opioid therapy.

GNH USA supplies Methadon Hcl Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methadone Hydrochloride is used within the opioid dependence and pain‑management pathways to provide controlled opioid agonism.

- Opioid dependence: stabilises patients by reducing withdrawal symptoms and cravings. - Opioid use disorder: supports maintenance therapy to prevent relapse. - Chronic pain: offers long‑acting analgesia for patients with severe, persistent pain unresponsive to non‑opioid options.

Methadone Hydrochloride may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea or vomiting - Constipation - Drowsiness or sedation - Sweating - Dry mouth - Dizziness

Serious or Rare Side Effects: - Respiratory depression - QT interval prolongation leading to arrhythmia - Severe hypotension - Adrenal insufficiency - Seizures - Allergic reactions such as rash or angioedema

When prescribing Methadone Hydrochloride, clinicians should observe several safety measures.

- Respiratory monitoring: assess breathing function, especially during initiation or dose changes. - Cardiac assessment: obtain baseline ECG and monitor QT interval. - Liver function: evaluate hepatic status before and during therapy. - Renal impairment: adjust dosing and monitor for accumulation. - Discontinuation: taper gradually to avoid precipitated withdrawal. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Methadone Hydrochloride interacts with several drug classes that can alter its safety or efficacy.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): risk of profound respiratory depression. - MAO inhibitors: can cause severe hypertension or serotonin syndrome. - QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics): increase risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise methadone plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticholinergic drugs: can exacerbate constipation. - Alcohol: additive CNS depression. - Herbal supplements (e.g., St. John’s wort): may affect metabolism.